Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Phase 2

Completed

Conditions: Breast Neoplasms
Neoplasm Metastasis

Interventions: Drug: Investigator's choice of treatment
Drug: afatinib
Drug: Vinorelbine

First Posted Date: 2011-09-27

Last Posted Date: 2015-09-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 121

Registration Number: NCT01441596

Locations: 🇰🇷
1200.67.82002 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
🇺🇸
1200.67.10105 Boehringer Ingelheim Investigational Site, Fullerton, California, United States
🇺🇸
1200.67.10108 Boehringer Ingelheim Investigational Site, Santa Barbara, California, United States

and more 37 locations

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: metformin placebo
Drug: metformin
Drug: linagliptin
Drug: linagliptin placebo

First Posted Date: 2011-09-22

Last Posted Date: 2014-11-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 689

Registration Number: NCT01438814

Locations: 🇧🇪
1218.60.32001 Boehringer Ingelheim Investigational Site, Genk, Belgium
🇧🇪
1218.60.32005 Boehringer Ingelheim Investigational Site, Ham, Belgium
🇧🇪
1218.60.32004 Boehringer Ingelheim Investigational Site, Natoye, Belgium

and more 87 locations

Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: tiotropium + olodaterol
Drug: olodaterol
Drug: tiotropium
Device: Respimat

First Posted Date: 2011-09-09

Last Posted Date: 2015-07-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2539

Registration Number: NCT01431287

Locations: 🇸🇰
1237.6.42106 Boehringer Ingelheim Investigational Site, Zilina, Slovakia
🇿🇦
1237.6.27002 Boehringer Ingelheim Investigational Site, Bellville, South Africa
🇺🇸
1237.6.01129 Boehringer Ingelheim Investigational Site, Henderson, Nevada, United States

and more 237 locations

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: tiotropium + olodaterol
Drug: olodaterol
Drug: tiotropium
Device: Respimat

First Posted Date: 2011-09-09

Last Posted Date: 2015-07-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2624

Registration Number: NCT01431274

Locations: 🇺🇸
1237.5.01028 Boehringer Ingelheim Investigational Site, Columbia, Maryland, United States
🇨🇿
1237.5.42005 Boehringer Ingelheim Investigational Site, Rokycany, Czech Republic
🇫🇮
1237.5.35802 Boehringer Ingelheim Investigational Site, Turku, Finland

and more 236 locations

GLORIA-AF Registry Program (Phase I)

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2011-09-05

Last Posted Date: 2014-03-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1096

Registration Number: NCT01428765

Locations: 🇭🇷
1160.114.04001 Boehringer Ingelheim Investigational Site, Opatija, Croatia
🇳🇱
1160.114.31008 Boehringer Ingelheim Investigational Site, Enschede, Netherlands
🇨🇳
1160.114.08017 Boehringer Ingelheim Investigational Site, Beijing, China

and more 59 locations

Olodaterol Bridging Study in Asthma

Phase 2

Withdrawn

Conditions: Asthma

Interventions: Device: Respimat
Drug: Olodaterol
Drug: Olodaterol & BI54903
Drug: BI54903

First Posted Date: 2011-09-05

Last Posted Date: 2011-11-22

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT01428622

Locations: 🇫🇷
1249.7.33003 Boehringer Ingelheim Investigational Site, Gières, France

Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ritonavir + afatinib
Drug: afatinib

First Posted Date: 2011-09-01

Last Posted Date: 2014-06-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT01426958

Locations: 🇩🇪
1200.151.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Relative Bioavailability of Bromhexine Given as Granules and Syrup in Healthy Volunteers (Clinical Phase I Study)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Bromihexine hydrochloride granules
Drug: Bromihexine hydrochloride syrup

First Posted Date: 2011-08-26

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 39

Registration Number: NCT01423721

Locations: 🇩🇪
65.129.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: high dose FDC
Drug: low dose FDC placebo
Drug: BI 10773 high dose
Drug: high dose FDC placebo
Drug: low dose FDC
Drug: high dose BI 10773 placebo
Drug: linagliptin
Drug: low dose BI 10773 placebo
Drug: BI 10773 low dose placebo
Drug: BI 10773 low dose
Drug: linagliptin placebo

First Posted Date: 2011-08-25

Last Posted Date: 2015-04-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1405

Registration Number: NCT01422876

Locations: 🇺🇸
1275.1.01043 Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States
🇺🇸
1275.1.01039 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
🇺🇸
1275.1.01003 Boehringer Ingelheim Investigational Site, Shreveport, Louisiana, United States

and more 208 locations

Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)

Phase 2

Completed

Conditions: Pulmonary Fibrosis

Interventions: Drug: Nintedanib
Drug: Pirfenidoneone

First Posted Date: 2011-08-16

Last Posted Date: 2017-03-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT01417156

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy